Managing Grade ≥3 Adverse Events
Dr. Hammers shares his experience with high-grade AEs in IO-TKI treated patients and how toxicities are mitigated/managed.
EP: 1.Initial Clinical Impression Description
EP: 2.Perspective on Initial Therapy Selection
EP: 3.CLEAR Study Efficacy Data Description
EP: 4.Immunotherapy-Based Regimen Efficacy/Safety Updates
EP: 5.Factors in Treatment Selection
EP: 6.Managing Grade ≥3 Adverse Events
EP: 7.Toxicity Management Approach
EP: 8.Quality of Life Considerations
EP: 9.Future Management of Advanced RCC
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
